| Name | Title | Contact Details |
|---|
Antigen Laboratories Inc is a Liberty, MO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Coeptis Therapeutics Holdings, Inc., together with its subsidiaries including Coeptis Therapeutics, Inc. and Coeptis Pharmaceuticals, Inc., (collectively "Coeptis"), is a biopharmaceutical company developing innovative cell therapy platforms for cancer that have the potential to disrupt conventional treatment paradigms and improve patient outcomes. Coeptis` product portfolio and rights are highlighted by a universal, multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), and intellectual property and knowhow related to the GEAR™ cell therapy and companion diagnostic platforms, which Coeptis is developing with VyGen-Bio and leading medical researchers at the Karolinska Institutet. Coeptis` business model is designed around maximizing the value of its current product portfolio and rights through in-license agreements, out-license agreements and co-development relationships, as well as entering into strategic partnerships to expand its product rights and offerings, specifically those targeting cancer. The Company is headquartered in Wexford, PA.
SpaLab is a San Marcos, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Kamada is focused on plasma-derived protein therapeutics with a commercial product portfolio and a late-stage product pipeline. The Company uses its proprietary platform technology and know-how for the extraction and purification of proteins from human plasma to produce Alpha-1 Antitrypsin (AAT) in a highly-purified, liquid form, as well as other plasma-derived Immune globulins. AAT is a protein derived from human plasma with known and newly-discovered therapeutic roles given its immunomodulatory, anti-inflammatory, tissue-protective and antimicrobial properties. The Company`s flagship product is GLASSIA®, the first liquid, ready-to-use, intravenous plasma-derived AAT product approved by the U.S. Food and Drug Administration. Kamada markets GLASSIA® in the U.S. through a strategic partnership with Baxalta (now part of Shire plc) and in other counties through local distributors. In addition to GLASSIA®, Kamada has a product line of six other pharmaceutical products administered by injection or infusion, that are marketed through distributors in more than 15 countries, including Israel, Russia, Brazil, India and other countries in Latin America and Asia. Kamada`s rabies immune globulin (Human) product received FDA approval for Post-Exposure Prophylaxis against rabies infection and is marketed in the U.S. through a partnership with Kedrion Biopharma. Kamada has late-stage products in development, including an inhaled formulation of AAT for the treatment of AAT deficiency and, in addition, its intravenous AAT is in development for other indications, such as type-1 diabetes, GvHD and prevention of lung transplant rejection. Kamada also leverages its expertise and presence in the plasma-derived protein therapeutics market by distributing more than 10 complementary products in Israel that are manufactured by third parties.
As the leading provider of targeted drug delivery (TDD) and infusion care, AIS Healthcare is committed to doing more of what matters. From pharmacies that put patient safety first to comprehensive services that enhance the entire care experience, we go beyond the expected across our two divisions. ● A center of excellence in high-risk intrathecal compounding, AIS Healthcare Targeted Drug Delivery prepares and ships more than 140,000 patient-specific dispenses annually to all 50 states. We also offer comprehensive care services to support patients and empower providers, including in-home pump care and care coordination services. ● At Advanced Infusion Care, we provide high-quality intravenous (IV) and subcutaneous (SubQ) immunoglobulin therapies and in-home care to more than 1,500 patients across the country. Our nationally accredited home infusion team, including infusion nurse specialists and clinical pharmacists, partner closely with physicians to provide the best possible infusion care. AIS Healthcare is dually accredited by URAC and the Accreditation Commission for Health Care (ACHC).